Scarica l'app Stockscreener
3.09
10.43%
-0.36
Dopo l'orario di chiusura:
3.11
0.02
+0.65%
Bioatla Inc Borsa (BCAB) Ultime notizie
BioAtla, Inc. Q2 2026: Revenue $6.5M, EPS $0.27— 10-Q Summary - TradingView
BioAtla (BCAB) turns Q2 2026 profit as cash falls and going concern risk emerges - Stock Titan
BioAtla, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Bioatla Inc (BCAB) Stock News Today - TradingKey
Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioAtla (BCAB) Climbs 3.9% to $3.46 as Buyers Step In Near SupportTick Index - dars.gov.et
BCAB Q2'26 Earnings: EPS estimate is (8.50) USD - TradingView
BCAB|Bioatla Inc|Price:3.460|Chg%:+0.130 - TradingKey
Bioatla Inc (BCAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bioatla Inc (BCAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bioatla Inc (BCAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioAtla, Inc. Revenue Breakdown – NASDAQ:BCAB - TradingView
Bioatla Inc (BCAB) Balance Sheet - TradingKey
Bioatla Inc (BCAB) Income Statement - TradingKey
TradingKey - TradingKey
BCAB|Bioatla Inc|Price:3.280|Chg%:-0.010 - TradingKey
BCAB|Bioatla Inc|Price:3.360|Chg%:-0.010 - TradingKey
Bioatla Inc (BCAB) Institutional Confidence - TradingKey
Bioatla Inc (BCAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioAtla Inc. (BCAB) Moves Higher: Biotech Stock Tests Key Resistance at $3.63Flat Correction - dars.gov.et
BioAtla Company Profile & Introduction - Moomoo
BioAtla Inc. (BCAB) Edges Lower Amid Consolidation, Testing Key Support LevelsNAAIM Exposure - dars.gov.et
BioAtla Shareholders Back Directors, Auditor and Pay Plan - The Globe and Mail
BioAtla, Inc. 8-K SEC Filing: Company Profile, Key Data, and Stock Information for July 2026 - Minichart
BCAB Q4 2025 Earnings: Substantial EPS Beat Signals Progress in Development PipelineAnalyst Earnings Estimate - po-news-eg.net
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Provides OptimismEarnings Miss Streak - DonanımHaber
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Drives Positive Investor ReactionPre-Earnings Setup - po-news-eg.net
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrower Net Loss Surpasses Expectations as Clinical Pipeline ProgressesBasic EPS Analysis - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Surprises Markets as Stock DeclinesTax Rate Impact - dars.gov.et
BioAtla Inc. (BCAB) Surges Nearly 6% as Shares Test Key Resistance LevelStraddle Setup - dars.gov.et
BCAB Q4 2025 Earnings: Narrowing Losses Beat Street Estimates as Stock Rises 4%Annual Financial Report - po-news-eg.net
Price to sales forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
Enterprise value to revenue forward of BioAtla, Inc. – NASDAQ:BCAB - TradingView
BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB) - TradingView
BCAB Forecast — Price Target — Prediction for 2027 - TradingView
BioAtla: BioAtla, Inc.Reverse Split Option Symbol: BCAB New Symbol: BCAB1 - Moomoo
BioAtla Inc. (BCAB) Jumps Over 7% as Biotech Momentum BuildsValue Area Low - dars.gov.et
Bioatla Inc (BCAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Surprises; Shares Edge HigherEarnings Surprise Report - dars.gov.et
BioAtla (BCAB) Q4 2025 Earnings: Narrowed Loss Beats Expectations as Stock AdvancesEarnings Expansion Phase - dars.gov.et
BioAtla Inc. (BCAB) Q4 2025 Earnings: Narrowed Loss and Positive Surprise Boost Investor Sentiment - dars.gov.et
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionEPS Consistency Score - newsline.com
BCAB Q4 2025 Earnings: Narrower Loss Surprises, Shares RiseLow Estimate Range - newsline.com
BioAtla Inc. (BCAB) Slips 2.5% as Shares Test Key Support ZoneBearish Pattern Stocks - newsline.com
BioAtla (BCAB) Slips 4.58% as Stock Nears Critical Support LevelTotal Put Call - newsline.com
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Offers Partial Offset Amid Stock DeclineAnalyst Consensus Shift - newsline.com
BCAB Q4 2025 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Pipeline ProgressROA Comparison - newsline.com
BioAtla (NASDAQ: BCAB) CFO logs non-sale share withholdings for RSU taxes - Stock Titan
BioAtla (BCAB) CMO has 494 shares withheld to cover RSU taxes - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineMargin Guidance - dars.gov.et
BioAtla (NASDAQ: BCAB) schedules 2026 virtual meeting and pay vote - Stock Titan
BCAB Q4 2025 Earnings: Narrower-Than-Expected Loss Driven by Operational DisciplineEarnings Whisper Number - newsline.com
BioAtla Inc. (BCAB) Slips Nearly 3% as Biotech Sector Faces HeadwindsProfitability Factor - The Legal Advocate
BioAtla Inc. (BCAB) Struggles Near Support as Selling Pressure PersistsCall Spread Alert - dars.gov.et
BioAtla Inc. (BCAB) Edges Higher as Stock Tests Key Resistance Near $3.95Schiff Line - The Legal Advocate
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):